MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318605 | Name: Rabeprazole Sodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rabeprazole Sodium Salt is a partially reversible gastric proton pump inhibitor. Rabeprazole Sodium Salt is an inhibitor of ATP4.

Chemical Structure

Rabeprazole Sodium
Rabeprazole Sodium
CAS#117976-90-6

Theoretical Analysis

MedKoo Cat#: 318605

Name: Rabeprazole Sodium

CAS#: 117976-90-6

Chemical Formula: C18H20N3NaO3S

Exact Mass:

Molecular Weight: 381.43

Elemental Analysis: C, 56.68; H, 5.29; N, 11.02; Na, 6.03; O, 12.58; S, 8.41

Price and Availability

Size Price Availability Quantity
100mg USD 250.00 2 Weeks
200mg USD 450.00 2 Weeks
500mg USD 750.00 2 Weeks
1g USD 1,450.00 2 Weeks
2g USD 2,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Rabeprazole Sodium; Pariet; Aciphex; Rabeprazole sodium salt; Rebeprazole sodium;3810, E; Aciphex; dexrabeprazole; E 3810; E3810; LY 307640; LY-307640; LY307640;
IUPAC/Chemical Name
sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
InChi Key
KRCQSTCYZUOBHN-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H20N3O3S.Na/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18;/h3-4,6-9H,5,10-12H2,1-2H3;/q-1;+1
SMILES Code
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3[N-]2)OCCCOC.[Na+]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in water
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Rabeprazole is a proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis and acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM.
In vitro activity:
This study found that rabeprazole can attenuate the cell viability of human gastric cancer cells by inactivating the ERK1/2 signaling pathway. These results demonstrate that since rabeprazole inhibits the viability of gastric cancer cells in vitro, it may serve as a novel antineoplastic agent. Reference: Oncol Lett. 2014 Oct;8(4):1739-1744. https://pubmed.ncbi.nlm.nih.gov/25202402/
In vivo activity:
Rabeprazole has no influence on the antitumor effect of cisplatin. Rabeprazole attenuates cisplatin -induced nephrotoxicity mainly through inhibiting OCT2-mediated cisplatin uptake, without interfering with its anti-tumor property of inducing apoptosis and necroptosis. Reference: Biochem Biophys Res Commun. 2022 Jul 5;612:91-98. https://pubmed.ncbi.nlm.nih.gov/35512462/
Solvent mg/mL mM
Solubility
Water 3.8 10.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 381.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Gu M, Zhang Y, Zhou X, Ma H, Yao H, Ji F. Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncol Lett. 2014 Oct;8(4):1739-1744. doi: 10.3892/ol.2014.2354. Epub 2014 Jul 16. PMID: 25202402; PMCID: PMC4156221. 2. Tamaro I, Genazzani A, Canonico P, Grosa G. Lack of in vitro interactions using human liver microsomes between rabeprazole and anticancer drugs. Eur J Drug Metab Pharmacokinet. 2009 Jan-Mar;34(1):19-26. doi: 10.1007/BF03191379. PMID: 19462924. 3. Chen SQ, Hu BF, Yang YR, He Y, Yue L, Guo D, Wu TN, Feng XW, Li Q, Zhang W, Wen JG. The protective effect of rabeprazole on cisplatin-induced apoptosis and necroptosis of renal proximal tubular cells. Biochem Biophys Res Commun. 2022 Jul 5;612:91-98. doi: 10.1016/j.bbrc.2022.04.107. Epub 2022 Apr 25. PMID: 35512462. 4. Martínez-Pérez Y, Nequiz-Avendaño M, García-Torres I, Gudiño-Zayas ME, López-Velázquez G, Enríquez-Flores S, Mendoza E, Saavedra E, Pérez-Tamayo R, León-Avila G, Olivos-García A. Rabeprazole inhibits several functions of Entamoeba histolytica related with its virulence. Parasitol Res. 2020 Oct;119(10):3491-3502. doi: 10.1007/s00436-020-06868-0. Epub 2020 Sep 4. PMID: 32886229.
In vitro protocol:
1. Gu M, Zhang Y, Zhou X, Ma H, Yao H, Ji F. Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncol Lett. 2014 Oct;8(4):1739-1744. doi: 10.3892/ol.2014.2354. Epub 2014 Jul 16. PMID: 25202402; PMCID: PMC4156221. 2. Tamaro I, Genazzani A, Canonico P, Grosa G. Lack of in vitro interactions using human liver microsomes between rabeprazole and anticancer drugs. Eur J Drug Metab Pharmacokinet. 2009 Jan-Mar;34(1):19-26. doi: 10.1007/BF03191379. PMID: 19462924.
In vivo protocol:
1. Chen SQ, Hu BF, Yang YR, He Y, Yue L, Guo D, Wu TN, Feng XW, Li Q, Zhang W, Wen JG. The protective effect of rabeprazole on cisplatin-induced apoptosis and necroptosis of renal proximal tubular cells. Biochem Biophys Res Commun. 2022 Jul 5;612:91-98. doi: 10.1016/j.bbrc.2022.04.107. Epub 2022 Apr 25. PMID: 35512462. 2. Martínez-Pérez Y, Nequiz-Avendaño M, García-Torres I, Gudiño-Zayas ME, López-Velázquez G, Enríquez-Flores S, Mendoza E, Saavedra E, Pérez-Tamayo R, León-Avila G, Olivos-García A. Rabeprazole inhibits several functions of Entamoeba histolytica related with its virulence. Parasitol Res. 2020 Oct;119(10):3491-3502. doi: 10.1007/s00436-020-06868-0. Epub 2020 Sep 4. PMID: 32886229.
1: Tan Y, Si X, Zhong L, Feng X, Yang X, Huang M, Wu C. Development and validation of dissolution testings in acidic media for rabeprazole sodium delayed-release capsules. Drug Dev Ind Pharm. 2016 Apr 11:1-9. [Epub ahead of print] PubMed PMID: 27066697. 2: Sabry SM, Abdel-Hay MH, Belal TS, Mahgoub AA. Development and validation of HPLC-DAD method for the simultaneous determination of amoxicillin, metronidazole and rabeprazole sodium. Application to spiked simulated intestinal fluid samples. Ann Pharm Fr. 2015 Sep;73(5):351-60. doi: 10.1016/j.pharma.2015.04.008. Epub 2015 May 27. PubMed PMID: 26024556. 3: Mohamed HM. A study of selective spectrophotometric methods for simultaneous determination of Itopride hydrochloride and Rabeprazole sodium binary mixture: Resolving sever overlapping spectra. Spectrochim Acta A Mol Biomol Spectrosc. 2014 Oct 28;136PC:1308-1315. doi: 10.1016/j.saa.2014.10.018. [Epub ahead of print] PubMed PMID: 25456673. 4: Ibrahim F, Wahba ME. Liquid chromatography coupled with fluorimetric detection and third derivative synchronous fluorescence spectroscopy as two analytical methods for the simultaneous determination of rabeprazole sodium and domperidone after derivatization with 4-chloro-7-nitrobenzofurazan. J Fluoresc. 2014 Jul;24(4):1137-47. doi: 10.1007/s10895-014-1394-z. Epub 2014 Jun 3. PubMed PMID: 24882601. 5: Swain S, Behera UA, Beg S, Sruti J, Patro ChN, Dinda SC, Rao ME. Design and characterization of enteric-coated controlled release mucoadhesive microcapsules of Rabeprazole sodium. Drug Dev Ind Pharm. 2013 Apr;39(4):548-60. doi: 10.3109/03639045.2012.676047. Epub 2012 Apr 18. PubMed PMID: 22512732. 6: Kumar N, Sangeetha D. Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Process-Related Impurities and Degradation Products of Rabeprazole Sodium in Pharmaceutical Formulation. Sci Pharm. 2013 Mar 17;81(3):697-711. doi: 10.3797/scipharm.1301-25. eCollection 2013. PubMed PMID: 24106668; PubMed Central PMCID: PMC3791934. 7: Nawaz MS. Validation and application of a new reversed phase HPLC method for in vitro dissolution studies of rabeprazole sodium in delayed-release tablets. J Anal Methods Chem. 2013;2013:976034. doi: 10.1155/2013/976034. Epub 2013 Aug 22. PubMed PMID: 24062966; PubMed Central PMCID: PMC3766580. 8: Tirpude RN, Puranik PK. Rabeprazole sodium delayed-release multiparticulates: Effect of enteric coating layers on product performance. J Adv Pharm Technol Res. 2011 Jul;2(3):184-91. doi: 10.4103/2231-4040.85539. PubMed PMID: 22171316; PubMed Central PMCID: PMC3217710. 9: Sawant RL, Hadawale SD, Dhikale GK, Bansode CA, Tajane PS. Spectrophotometric methods for simultaneous estimation of rabeprazole sodium and aceclofenac from the combined capsule dosage form. Pharm Methods. 2011 Jul;2(3):193-7. doi: 10.4103/2229-4708.90362. PubMed PMID: 23781455; PubMed Central PMCID: PMC3658056. 10: Rao PS, Ray UK, Gupta PB, Rao DV, Islam A, Rajput P, Mukkanti K. Identification, isolation and characterization of new impurity in rabeprazole sodium. J Pharm Biomed Anal. 2010 Aug 1;52(4):620-4. doi: 10.1016/j.jpba.2010.01.034. Epub 2010 Jan 25. PubMed PMID: 20153594. 11: Osman AO. Spectrofluorometry, thin layer chromatography, and column high-performance liquid chromatography determination of rabeprazole sodium in the presence of its acidic and oxidized degradation products. J AOAC Int. 2009 Sep-Oct;92(5):1373-81. Erratum in: J AOAC Int. 2009 Nov-Dec;92(6):203A. Osman, Afaf [corrected to Osman, Afaf Osman]; Osman, Mohamed [removed]. PubMed PMID: 19916375. 12: Gandhi SV, Khan SI, Jadhav RT, Jadhav SS, Jadhav GA. High-performance thin-layer chromatographic determination of rabeprazole sodium and domperidone in combined dosage form. J AOAC Int. 2009 Jul-Aug;92(4):1064-7. PubMed PMID: 19714973. 13: Ono S, Kato M, Ono Y, Imai A, Yoshida T, Shimizu Y, Asaka M. Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules. J Gastroenterol Hepatol. 2009 Apr;24(4):639-45. doi: 10.1111/j.1440-1746.2008.05644.x. Epub 2008 Nov 20. PubMed PMID: 19032447. 14: Pillai S, Singhvi I. Quantitative estimation of itopride hydrochloride and rabeprazole sodium from capsule formulation. Indian J Pharm Sci. 2008 Sep;70(5):658-61. doi: 10.4103/0250-474X.45411. PubMed PMID: 21394269; PubMed Central PMCID: PMC3038297. 15: Moneeb MS. Chemometric determination of rabeprazole sodium in presence of its acid induced degradation products using spectrophotometry, polarography and anodic voltammetry at a glassy carbon electrode. Pak J Pharm Sci. 2008 Jul;21(3):214-24. PubMed PMID: 18614415. 16: Sabnis SS, Dnvandev DN, Jadhav VY, Gandhi SV. Column reversed-phase high-performance liquid chromatographic method for simultaneous determination of rabeprazole sodium and domperidone in combined tablet dosage form. J AOAC Int. 2008 Mar-Apr;91(2):344-8. PubMed PMID: 18476346. 17: Mbah CJ. Kinetics of decomposition of rabeprazole sodium in aqueous solutions determined by high performance liquid chromatography. Pharmazie. 2007 Feb;62(2):112-4. PubMed PMID: 17341029. 18: Garcia CV, Paim CS, Steppe M, Schapoval EE. Development and validation of a dissolution test for rabeprazole sodium in coated tablets. J Pharm Biomed Anal. 2006 Jun 7;41(3):833-7. Epub 2006 Mar 2. PubMed PMID: 16513316. 19: Pingili RR, Jambula MR, Ganta MR, Ghanta MR, Sajja E, Sundaram V, Boluggdu VB. Identification and synthesis of potential impurities of rabeprazole sodium. Pharmazie. 2005 Nov;60(11):814-8. PubMed PMID: 16320941. 20: Garcia CV, Paim CS, Steppe M. New liquid chromatographic method for determination of rabeprazole sodium in coated tablets. J AOAC Int. 2004 Jul-Aug;87(4):842-6. PubMed PMID: 15295877.

View History

JCC76

JCC76